Evidence Table 121. KQ3—Dichotomous—Bleeding

| **Author Year**  **Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug**  **(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ferraro 200922  Parallel | Bleeding: Erythrocyturia Class1 | Unclear | Ramipril (10) | Omega-3 | 15 | 5 | No Treatment | 15 | 0 |  | 2 vs. 10 at baseline were at level 1 erythrocyturia. | Medium |
| Ferraro 200922  Parallel | Bleeding: CE (erythocyturia 2 | Unclear | Ramipril (10) | Omega-3 | 15 | -4 | No Treatment | 15 | 0 |  |  | Medium |
| Ferraro 200922  Parallel | Bleeding: CE (erythocyturia 3 | Unclear | Ramipril (10) | Omega-3 | 15 | -1 | No Treatment | 15 | 0 |  |  | Medium |
| Lee 200836  Parallel |  | At high risk for CHD | Warfarin (3.5) | Ginseng | 12 |  | No Treatment | 13 | 0 |  | No events occurred. No data reported. | Medium |
| Gardner 200723  Parallel | Nosebleed and/or unusual bleeding | Mixed : Moderate to high | ASA (325) | Gingko baloba | 30 | 5 | Placebo | 30 | 4 |  |  | Low |
| Whitlock 200772  Parallel |  | At high risk for CHD | Warfarin (2) | Vitamin K | 12 | 0 | Placebo | 16 | 0 |  |  |  |
| Sconce 200761  Parallel |  | Unclear | Warfarin (3.8-4.4 vs. 3.3-3.4) | Vitamin K | 35 | 0 | Placebo | 33 | 0 |  |  | Medium |
| Macan 200640  Parallel | Incidence of hemorrhager | Unclear | Warfarin (NR) | Garlic | 22 | 0 | Placebo | 26 | 0 | P: 1.000 (Crude event risk ratio) | N included is unclear: Unclear (66 enrolled, 52 randomized total) | Medium |

| Evidence Table 121. KQ3—Dichotomous—Bleeding (continued) | | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author Year**  **Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug**  **(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| Macan 200640  Parallel | Epitaxis | Unclear | Warfarin (NR) | Garlic | 22 | 0 | Placebo | 26 | 0 |  | Other dichotomous outcomes assessed in this study (not specifically relevant): change in warfarin dosage | Medium |
| Macan 200640  Parallel | Clinically relevant bleeding: Hemoptysis | Unclear | Warfarin (NR) | Garlic | 22 | 0 | Placebo | 26 | 0 |  |  | Medium |
| Macan 200640  Parallel | Clinically relevant bleeding: bloody stools | Unclear | Warfarin (NR) | Garlic | 22 | 0 | Placebo | 26 | 0 |  | Total included per arm is unclear (66 enrolled, 52 randomized total) | Medium |
| Macan 200640  Parallel | hemorrhage into organs | Unclear | Warfarin (NR) | Garlic | 22 | 0 | Placebo | 26 | 0 |  | Total included per arm is unclear (66 enrolled, 52 randomized total) | Medium |
| Macan 200640  Parallel | Clinically relevant bleeding: hemarthrosis | Unclear | Warfarin (NR) | Garlic | 22 | 0 | Placebo | 26 | 0 |  | Total included per arm is unclear (66 enrolled, 52 randomized total) | Medium |
| Macan 200640  Parallel | Clinically relevant bleeding: hematomas | Unclear | Warfarin (NR) | Garlic | 22 | 0 | Placebo | 26 | 0 |  | Total included per arm is unclear (66 enrolled, 52 randomized total) | Medium |
| Macan 200640  Parallel | Clinically relevant bleeding?: brusing | Unclear | Warfarin (NR) | Garlic | 22 | 0 | Placebo | 26 | 0 |  | Total included per arm is unclear (66 enrolled, 52 randomized total) | Medium |
| Steiner 199562  Parallel | Hemorrhagic event | At high risk for CHD | ASA (325) | Vitamin E | 52 | 3 | Placebo | 48 | 3 |  |  | Low-medium |
| Kaul 199234  Parallel | bleeding complications (non-specific) | At high risk for CHD | Calcium channel blocker, ASA (NR) | Omega-3 | 58 | 0 | No Treatment | 49 | 0 |  |  | Low-medium |
| Bender 19988  Parallel | Bleeding | Unclear | Warfarin (NR) | Omega-3 | 6 | 0 | No Treatment | 5 | 0 |  |  | High |
| Bender 19988  Parallel | minor brusing | Unclear | Warfarin (NR) | Omega-3 | 6 |  | No Treatment | 5 |  |  | numeric data is not separated by groups. One episode of bruising occured but no group designation reported. | High |
| Dehmer 198817  Parallel | bleeding complications | At high risk for CHD | Aspirin (325)+ Dipyridamole (225) + Calcium channel blockers (NR) | Omega-3 | 43 | 0 | No Treatment | 39 | 0 |  |  | Medium |
| Dehmer 198817  Parallel | serious passive hematoams | At high risk for CHD | Aspirin (325)+ Dipyridamole (225) + Calcium channel blockers (NR) | Omega-3 | 43 | 3 | No Treatment | 39 | 1 |  |  | Medium |
| Eritsland 199621  Parallel | bleeding complications (major and minor) | At high risk for CHD | Warfarin (NR) | Omega-3 | 174 | 2 | No Treatment | 145 | 2 |  |  | Medium |
| Eritsland 199621  Parallel | bleeding complications (major and minor) | At high risk for CHD | Aspirin (300) | Omega-3 | 143 | 3 | No Treatment | 148 | 2 |  |  | Medium |
| Mueller 199151  Crossover | N/A | Mixed:  Low and/or Moderate | ASA (325 – single dose) | Omega-3 |  | 0 | Placebo |  | 0 |  |  | Medium |